Herpesvirus vaccines

Infectious Disease Clinics of North America

Volumn 13, Issue 1, 1999, Pages 61-81

  Krause, P R ^a   Straus, S E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; CYTOMEGALOVIRUS VACCINE; EPSTEIN BARR VIRUS VACCINE; HERPES SIMPLEX VACCINE; HERPES VACCINE; LIVE VACCINE; VIRUS VACCINE;

CEREBROVASCULAR DISEASE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEVER; HERPES SIMPLEX; HUMAN; INJECTION SITE; NEUROPATHY; PREGNANCY COMPLICATION; RASH; REVIEW; CLASSIFICATION; HERPES VIRUS; HERPES VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0032938795     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70043-X     Document Type: Article

References (88)

1. S.P. Adler Current prospects for immunization against cytomegalovirus disease Infectious Agents and Disease 5 1996 29
2. S.P. Adler S.E. Starr S.A. Plotkin Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age J Infect Dis 171 1995 26
3. S.G. Anderson J. Hamilton S. Williams An attempt to vaccinate against herpes simplex Aust J Exp Biol Med Sci 28 1950 579
4. A. Arbeter S.E. Starr S.A. Plotkin Varicella vaccine studies in healthy children and adults Pediatrics 78 suppl 1986 748
5. Y. Asano Varicella vaccine: The Japanese experience J Infect Dis 174 suppl 3 1996 S310
6. Y. Asano S. Hirose S. Iwayama Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination Biken J 25 1987 43
7. Y. Asano N. Itakura Y. Hiroishi Viremia is present in incubation period in nonimmunocompromised children with varicella J Pediatr 106 1985 69
8. Y. Asano S. Suga T. Yoshikawa Experience and reason: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine Pediatrics 94 1994 524
9. Y. Asano T. Yoshikawa S. Suga Postexposure prophylaxis of varicella in family contacts by oral acyclovir Pediatrics 92 1993 219
10. Balfour H.H. Jr P.K. Welo G.W. Sachs Cytomegalovirus vaccine trial in 400 renal transplant candidates Transplant Proc 17 1985 81
11. J. Barnes Peptide-based EBV vaccine in phase I trial Pharma Weekly 1 1995 11
12. H.H. Bernstein E.P. Rothstein B.M. Watson Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine Pediatrics 92 1993 833
13. N. Bourne G.N. Milligan M.R. Schleiss DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2 Vaccine 14 1996 1230
14. M.E.G. Boursnell C. Entwisle D. Blakeley A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease J Infect Dis 175 1997 16
15. W.J. Britt L. Vugler E.B. Stephen Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB) J Virol 62 1988 3309
16. P.A. Brunell C.F. Geiser V. Novelli Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia Pediatrics 79 1987 922
17. P.A. Brunell J. Taylor C.F. Geiser Risk herpes zoster in children with leukemia: Varicella vaccine compared with history of chickenpox Pediatrics 77 1981 53
18. Cadoz M, Micoud M, Seigneurin JM: Phase I trial of R7020: A live-attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Presented at The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992
19. Centers for Disease Control and Preventions Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 45 RR-11 1996 1
20. T.A. Cha E. Tom G.W. Kemble Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains J Virol 70 1996 78
21. J.I. Cohen Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens J Infect Dis 177 1998 1390
22. Committee on Infectious Diseases of the American Academy of Pediatrics Recommendations for the use of live attenuated varicella vaccine Pediatrics 95 1995 791
23. L. Corey P.G. Spear Infections with herpes simplex viruses N Engl J Med 314 1986 686
24. D.J. Dargan J.H. Subak-Sharpe The effect of herpes simplex virus type 1 L-particles on virus entry, replication, and the infectivity of naked herpesvirus DNA Virology 239 1997 378
25. De Moragas J.M. R.R. Kierland The outcome of patients with herpes zoster Arch Dermatol 75 1957 193
26. D.T. Fleming G.M. McQuillan R.E. Johnson Herpes simplex virus type 2 in the United States, 1976 to 1994 N Engl J Med 337 1997 1105
27. E.L. Ford-Jones I. Kitai L. Davis Cytomegalovirus infections in Toronto child-care centers: A prospective study of viral excretion in children and seroconversion among day-care providers Pediatr Infect Dis J 15 1996 507
28. K.B. Fowler S. Stagno R.F. Pass The outcome of congenital cytomegalovirus infection in relation to maternal antibody status N Engl J Med 326 1992 663
29. W.S. Gallichan K.L. Rosenthal Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization J Infect Dis 177 1998 1155
30. A.A. Gershon P. LaRussa S. Steinberg The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox J Infect Dis 173 1996 450
31. A.A. Gershon N. Mervish P. LaRussa Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection J Infect Dis 176 1997 1496
32. D.H. Gilden A.N. Dueland M.E. Devlin Varicella-zoster virus reactivation without rash J Infect Dis 166 suppl 1 1992 S30
33. E. Gonczol K. Berensci S. Pincus Preclinical evaluation of an ALVAC (canarypox)—human cytomegalovirus glycoprotein B vaccine candidate Vaccine 13 1995 1080
34. S.Y. Gu T.M. Huang L. Ruan First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen Dev Biol Stand 84 1995 171
35. M.E. Halloran S.L. Cochi M. Wharton L. Fehrs Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children Am J Epidemiol 140 1994 81
36. I. Hardy A.A. Gershon S.P. Steinberg P. LaRussa The incidence of zoster after immunization with live attenuated varicella vaccine N Engl J Med 325 1991 1545
37. R.E. Hope-Simpson The nature of herpes zoster: A long-term study and a new hypothesis Proc R Soc Lond B Biol Sci 58 1965 9
38. R.E. Johnson A.J. Nahmias L.S. Magder A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States N Engl J Med 321 1990 7
39. N. Katsushima N. Yazaki M. Sakamoto Application of a live varicella vaccine to hospitalized children and its follow-up study Biken J 25 1982 29
40. Kemble G, Duke G, Winter R, Spaete R: A new generation of live, attenuated cytomegalovirus (CMV) vaccine strains. Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996
41. A.B. Kern B.L. Schiff Vaccine therapy in recurrent herpes simplex Dermatology 89 1964 944
42. R. Khanna S.R. Burrows D.J. Moss Immune regulation in Epstein-Barr virus-associated diseases Microbiol Rev 59 1995 387
43. R.G. Kost S.E. Straus Postherpetic neuralgia—pathogenesis, treatment, and prevention N Engl J Med 335 1996 32
44. P.R. Krause D.M. Klinman Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine J Pediatr 127 1995 518
45. J.D. Kriesel S.L. Spruance R.A. Daynes B.A. Araneo Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease J Infect Dis 173 1996 536
46. P. LaRussa S. Steinberg A. Gershon Varicella vaccine for immunocompromised children: Results of collaborative studies in the United States and Canada J Infect Dis 174 suppl 3 1996 S320
47. R. Lawrence A.A. Gerson R. Holzman S.P. Steinberg The risk of zoster after varicella vaccination in children with leukemia N Engl J Med 318 1988 543
48. Leroux-Roels G, Moreau E, Desombere I, et al: Safety, humoral and cellular immune responses of three different doses of glycoprotein D(gD2t) in herpes simplex vaccine with aluminum and MPL. Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1997
49. M.J. Levin A.R. Hayward The varicella vaccine: Prevention of herpes zoster Infect Dis Clin North Am 10 1996 657
50. T.A. Lieu S.L. Cochi S.B. Black Cost-effectiveness of a routine varicella vaccination program for U.S. children JAMA 271 1994 375
51. P. Ljungman B. Lonnqvist G. Gahrton Clinical and subclinical reactivation of varicella-zoster virus in immunocompromised patients J Infect Dis 153 1986 840
52. Malinoski FJ, Linden J, Smith J, et al: Immunization of plasmapharesis donors with cytomegalovirus vaccine composed of gB glycoprotein and MF-59 adjuvant. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997
53. E. Manickan R.J. Rouse Z. Yu Genetic immunization against herpes simplex virus: Protection is mediated by CD4+ T lymphocytes J Immunol 155 1995 259
54. Marshall GS, Frey S, Pass R, et al: Safety and immunogenicity of CMV gBMF59 vaccine in healthy seronegative adults. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997
55. B. Meignier R. Whitley B. Roizman In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotu trivargatus) J Infect Dis 162 1990 313
56. Merck & Co Varivax (Varicella Virus Vaccine Live [Oka/Merck]) package circular Physicians' Desk Reference ed 52 1998 Medical Economics Co. Montvale, NJ 1762
57. G.J. Mertz R. Ashley R.L. Burke Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection J Infect Dis 161 1990 653
58. D.M. Miller B.M. Rahill J.M. Boss Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway J Exp Med 187 1998 675
59. A.J. Morgan Epstein-Barr virus vaccines Vaccine 10 1992 563
60. R.F. Pass A.M. Duliege S.B. Boppana Immunogenicity of a recombinant CMV gB Vaccine Pediatr Res 37 1995 185A
61. H.L. Ploegh Viral strategies of immune evasion Science 280 1998 248
62. S.A. Plotkin J. Farquhar E. Hornberger Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus J Infect Dis 134 1976 470
63. S.A. Plotkin R. Higgins J.B. Kurtz Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients Transplantation 58 1994 1176
64. A. Porath R.A. McNutt L.M. Smiley K.A. Weigle Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease Rev Infect Dis 12 1990 31
65. M.W. Ragozzino L.J.D. Melton L.T. Kurland Population-based study of herpes zoster and its sequelae Medicine (Baltimore) 61 1982 310
66. J.J. Rooney J.M. Felser J.M. Ostrove S.E. Straus Acquisition of genital herpes from an asymptomatic sexual partner N Engl J Med 314 1986 1561
67. A.H. Ross Modification of chickenpox in family contacts by administration of gamma-globulin N Engl J Med 267 1962 369
68. D.R. Snydman B.G. Werner B.H. Heinze-Lacy Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients N Engl J Med 317 1987 1049
69. F.C. Spector E.R. Kern J. Palmer Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs J Infect Dis 177 1998 143
70. R.W. Spingarn J.A. Benjamin Universal vaccination against varicella N Engl J Med 338 1998 683
71. S. Stagno R.F. Pass M.E. Dworsky Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection N Engl J Med 306 1982 945
72. W.E. Stamm H.H. Handsfield A.M. Rompalo The association between genital ulcer disease and acquisition of HIV infection in homosexual men JAMA 260 1988 1429
73. S.E. Straus L. Corey R.L. Burke Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes Lancet 343 1994 1460
74. S.E. Straus J.M. Ostrove G. Inchauspe NIH conference. Varicella-zoster virus infections: Biology, natural history, treatment, and prevention Ann Intern Med 108 1988 221
75. S.E. Straus B. Savarese M. Tigges Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine J Infect Dis 167 1993 1045
76. S.E. Straus A. Wald R.G. Kost Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial J Infect Dis 176 1997 1129
77. M. Takahashi Clinical overview of varicella vaccine: Development and early studies Pediatrics 78 1986 736
78. M. Takahashi T. Otsuka Y. Okuno Live vaccine used to prevent the spread of varicella in children in hospital Lancet 2 1974 1288
79. D.A. Thorley-Lawson K. Geilinger Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity Proc Natl Acad Sci U S A 77 1980 5307
80. T. Varis T. Vesikari Efficacy of high-titer live attenuated varicella vaccine in healthy young children J Infect Dis 174 suppl 3 1996 S330
81. D.J. Vugia C.L. Peterson H.B. Meyers Invasive group A streptococcal infections in children with varicella in southern California Pediatr Infect Dis J 15 1996 146
82. A. Wald Virologic characteristics of subclinical and symptomatic genital herpes infections N Engl J Med 333 1995 770
83. E.H. Wasmuth W.J. Miller Sensitive ELISA for antibody to varicella-zoster virus using purified VZV glycoprotein antigen J Med Virol 32 1990 189
84. R.E. Weibel B.J. Neff B.J. Kuter Live attenuated varicella vaccine: Efficacy trial in healthy children N Engl J Med 310 1984 1409
85. M. Wharton The epidemiology of varicella-zoster virus infections Infect Dis Clin North Am 10 1996 571
86. C.J. White B.J. Kuter A. Ngai Modified cases of chickenpox after varicella vaccination: Correlation of protection with antibody response Pediatr Infect Dis J 11 1992 19
87. R.J. Whiteley E.R. Kern S. Chatterjee Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models J Clin Invest 91 1993 2837
88. A. Wilson M. Sharp C.M. Koropchak Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation J Infect Dis 165 1992 119